Survey to Assess Why People Are Not Responding to Treatment in Hypertension

This study will describe the factors influencing the physician in face of elevated blood pressure in already treated patients

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Arterial Hypertension Cardiovascular Diseases Hypertension Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Many Locations, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Men or women over 18
Hypertensive patients
Uncontrolled hypertension (blood pressure >/=140/90 mmHg on the day of consultation or >/=130/80 mmHg in diabetic patients or in patients suffering from kidney failure, or in elderly patients with a systolic blood pressure >/=150 mmHg (in the absence of orthostatic hypotension)
Patients treated with a combination, fixed or not, of Renin-Angiotensin System Blocker (RASB) + Hydrochlorothiazide (HCTZ)
Patients examined in common medical care practice, whatever the reason for consultation
Patients informed of the study

Treatment and study plan

Telmisartan (Kinzal/Pritor, BAY68-9291)

Drug

Patients under daily life treatment receiving Pritor according to local drug information.

Primary outcomes

Percentage of patients, according to the level of cardiovascular risk, who, at the end of the visit:- do not present any modification of hypertension treatment (therapeutic inertia) - present a change in the hypertension therapeutic

Time frame: on day 1

Secondary outcomes

Analyses of the factors that had an impact on the therapeutic decision

Time frame: on day 1

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Collaborators

International Clinical Trials Association

Registry information

Official study title

Observational Survey Assessing the Factors of Treatment Intensification in Uncontrolled Hypertensive Patients Under a Combination Therapy, Either Fixed or Not, of a Renin-Angiotensin System Blocker (RASB) and Hydrochlorothiazide (HCTZ), According to Their Level of Cardiovascular Risk.

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2010
First posted: Feb 19, 2010
Registry last updated: Nov 2, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed